Completed PHASE4 INTERVENTIONAL NCT00417066

Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders

The Flexible GnRH Antagonist Protocol Provides Better Results (IVF Outcomes) Than Flare up GnRH Agonist Protocol in Poor Responders

Sponsor: Eugonia

Conditions Infertility Premature Ovarian Failure

Interventions Arvekap 0.1mg (Triptorelin, Ipsen, France) Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)

Updated 5 times since 2017 Last updated: Dec 13, 2013 Started: Sep 30, 2003 Completion: Jul 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Infertility and Premature Ovarian Failure and is currently completed. Eugonia leads this study, which shows 5 recorded versions since 2003 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Sep 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eugonia

Data source: Eugonia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Athens, Greece